Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study

INTRODUCTION: Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)—collectively named inflammatory arthritis (IA). However, the costs...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Adv Ther
Autores principales: Dalén, Johan, Luttropp, Karin, Svedbom, Axel, Black, Christopher M., Kachroo, Sumesh
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444358/
https://ncbi.nlm.nih.gov/pubmed/32647910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01425-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares